Links from this page to related variants, conditions, drugs and topics are not included for automated readers. Those connections are the Gene Knowledge Graph and are licensed as data: https://www.mygenelog.com/license

Standard

Plateletcrit

CHEK2 · rs186430430

Strength of the evidence

2 / 4

Its strongest genetic-study result is p = 10−32, with 13 associations in the GWAS Catalog.

How this is scored

4: ClinVar disease-causing, reviewed by an expert panel or a guideline (3–4 stars). 3: ClinVar, several labs agreeing (2 stars), or a genetic study at p ≤ 10−50. 2: ClinVar from one lab (1 star), or p ≤ 10−20. 1: ClinVar submitted without criteria (0 stars), or genome-wide significance (p ≤ 5×10−8). The higher of the two counts. It says how solid the evidence is, not whether it matters for a particular person.

What the study found

Who was studied 164,339 European ancestry individuals.

The effect Each copy of the C allele shifted the measure 0.231 higher (95% confidence interval 0.15-0.31); p = 6 × 10−9.

How common The C allele had a frequency of about 0% in the people studied.

Where it sits Chromosome 22, band 22q12.1 — in an intron of CHEK2.

How common each version is

CT
World gnomAD
C 0.2% · T 99.8%
World 1000 Genomes
C 0.1% · T 99.9%
World TOPMed
C 0.1% · T 99.9%

By ancestry gnomAD

European (non-Finnish)
T 99.8%
African / African American
T 100.0%
Finnish
C 0.9% · T 99.1%
Ashkenazi Jewish
T 99.8%

The share of all copies of this position that are each version. Source: the population studies published in dbSNP (US NCBI); each row names its study. The ancestry rows are gnomAD's own groups (via Ensembl), as the survey defines them, not races. No Korean figure for this position yet.

What each result means

C/C Two copies of the version the research linked to Plateletcrit. That is the strongest link of the three results. A link in a study is not a diagnosis.
C/T One copy of the version the research linked to Plateletcrit. That is a smaller link than two copies.
T/T No copy of the version the research linked to Plateletcrit. This is the starting point the study compared everyone against.
Source

Quoting this page

Licensed CC BY-NC 4.0: free to read, share and adapt for non-commercial use, naming MyGeneLog™ and linking the exact page. Commercial use, including training or serving a commercial AI system, needs a licence — https://www.mygenelog.com/license

Plateletcrit (rs186430430). MyGeneLog™. https://www.mygenelog.com/variants/rs186430430

← See all variants